Kathleen J. Lively

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

L. Trippa, N. Munshi, J. Laubach, 2019, Blood.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma

L. Trippa, N. Munshi, J. Laubach, 2018, British journal of haematology.

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

J. Lohr, J. Laubach, P. Richardson, 2019, Blood.

A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

J. Lohr, J. Laubach, P. Richardson, 2018 .